The Proposed Combination entails Platinum Poppy acquiring ordinary shares in Berhyanda and Berhyanda MidCo, along with extending shareholder debt. This will result in Platinum Poppy obtaining an indirect non-voting economic interest in Suven Pharmaceuticals Limited (Suven), as Berhyanda currently holds a 50.1% shareholding in Suven.

Platinum Poppy, a restricted scope company incorporated in the Abu Dhabi Global Market and ultimately benefiting Abu Dhabi Investment Authority (ADIA), is solely established for investing in Berhyanda and Berhyanda MidCo. ADIA, an independent investment institution established by the Government of the Emirate of Abu Dhabi, manages a diversified global investment portfolio across numerous asset classes, including equities, bonds, real estate, and private equity. In India, ADIA has made sector-agnostic investments in various sectors such as real estate, financial services, insurance, pharmaceuticals, and agrochemicals.

Berhyanda and Berhyanda MidCo are wholly owned by funds managed by Advent International, L.P., and serve as investment holding companies.

Suven Pharmaceuticals Limited is a publicly listed company in India, listed on BSE Limited and National Stock Exchange Limited. Established in 2018, Suven is engaged in manufacturing and selling active pharmaceutical ingredients and intermediates in India, as well as providing contract development and manufacturing services for intermediates.